593 results on '"Agnelli, Luca"'
Search Results
52. Supplementary Table 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome
53. Supplementary Figure 2 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma
54. Supplementary Methods from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
55. Supplementary Figure 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome
56. Supplementary Figure 5 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
57. Supplementary Figure 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
58. Supplementary Figure 4 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features
59. Supplementary Figure 1 from Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors
60. Supplementary Figure 3 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
61. Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target
62. Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts
63. Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing
64. Evaluation of clinical benefit and progression-free survival ratio of targeted treatments in a prospective cohort study of patients with biliary tract cancers.
65. ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
66. The Genomics of Multiple Myeloma and Its Relevance in the Molecular Classification and Risk Stratification of the Disease
67. Identification of the Proteasome Subunits PSMB4 and PSMD4 As Novel Targets in Multiple Myeloma Patients Carrying 1q21 Amplification
68. A 7-Gene Signature in Unmanipulated Leukaphereses Correlates with in-Vivo CAR T-Cell Expansion and Survival of Lymphoma Patients Receiving Tisagenlecleucel or Axicabtagene Ciloleucel Therapy
69. Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples
70. Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements
71. MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers
72. Molecular analyses of metastatic collecting ducts renal cell carcinoma from the phase 2 prospective trial of cabozantinib as first-line treatment (BONSAI trial Meeturo 2).
73. PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 < 50%: A multiomics approach.
74. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma
75. Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
76. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers
77. PSMB4 and PSMD4 Are Correlated with 1q21 Amplification in CD138 + Plasma Cells: New Potential Druggable Targets in Myeloma Patients
78. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma
79. Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells
80. PYGO2-MDR1 Axis in Multiple Myeloma Patients with 1q21 Amplification As Promising Target to Overcome Carfilzomib Resistance
81. A Novel Model Combining Circulating Absolute Monocyte Counts and a Four-Gene Monocyte Signature in Leukapheresis Identifies Lymphoma Patients at Very High Risk of Progression after Tisagenlecleucel or Axicabtagene Ciloleucel Therapy
82. Next-generation sequencing in multiple myeloma: insights into the molecular heterogeneity of the disease
83. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications
84. Editorial: Genomics of Lymphoproliferative Disease
85. Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients
86. The UpSMART Accelerator: driving digital innovation to change the conduct of early phase cancer medicine trials
87. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma
88. The Genomics of Multiple Myeloma and Its Relevance in the Molecular Classification and Risk Stratification of the Disease
89. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes
90. Improved risk stratification in myeloma using a microRNA-based classifier
91. Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia
92. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles
93. B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia
94. CRITICAL ANALYSIS OF TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL REGULATORY NETWORKS IN MULTIPLE MYELOMA
95. Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations
96. Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability
97. Revealing the Impact of Structural Variants in Multiple Myeloma
98. Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma
99. NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome
100. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.